| Literature DB >> 31700137 |
Mauricette Michallet1, Peter Dreger2, Mohamad Sobh3, Linda Koster4, Jennifer Hoek4, Ariane Boumendil5, Christof Scheid6, Christopher P Fox7, Gerald Wulf8, William Krüger9, Michel van Gelder10, Paolo Corradini11, Domenico Russo12, Jakob Passweg13, Hélène Schoemans14, Wolfgang Bethge15, Nicolaas Schaap16, Jan Cornelissen17, Paul Browne18, Nadira Durakovic19, Lutz Muller20, Silvia Montoto21, Nicolaus Kroger22, Johannes Schetelig23.
Abstract
The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31700137 DOI： 10.1038/s41409-019-0742-7
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483